Fig. 2From: Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in ChinaTornado plots for one-way deterministic sensitivity analysis of the PEACE study population. (A and B) are the results from the Chinese healthcare perspective, C and D are the results from the Chinese private payer perspectiveThe dotted line shows the willingness-to-pay threshold of CNY 257094 per quality-adjusted life-year gained; C_, Cost; CNY, Chinese yuan, CV, cardiovascular; ER_, event rate; EV, expected value; HR_, Hazard ratio; ICER, incremental cost-effectiveness ratio; IE_, Intervention effect; MI, myocardial infarction; RV_, revascularization; U_, Utility; WTP, willingness-to-payBack to article page